An article in Benzinga highlights Syqe® Medical’s innovative SyqeAir Inhaler, emphasizing its role in addressing the global challenge of cannabis overdose through metered dosing. CEO of SyqeAir, Hagit Kamin, discusses how the Inhaler and Cartridges allow patients to achieve fast relief in the intensity of chronic neuropathic pain and PTSD symptoms without the risk of overdose. The article underscores Syqe®’s commitment to a safer yet equally effective medical cannabis treatment and marks another prestigious acknowledgment for the company. Read the full article>>

Australian veterans gain subsidized access to SyqeAir Inhaler
Australian veterans now have subsidised access to the SyqeAir Inhaler, following TGA approval — a major step in expanding safe, metered medical cannabis treatment through government-supported programs.